通过天眼查大数据分析，创业慧康科技股份有限公司共对外投资了57家企业，参与招投标项目5000次， 知识产权方面有商标信息43条，专利信息114条，此外企业还拥有行政许可74个。 来源：金融界 创业慧康最新一期业绩显示，截至2025一季报，公司营业总收入2.90亿元、同比减少22.67%，归属净利 润1564.74万元，同比减少226.60%，扣非净利润2795.93万元，同比减少389.48%，流动比率2.758、速动 比率2.423、资产负债率19.82%。 天眼查商业履历信息显示，创业慧康科技股份有限公司，成立于1997年，位于杭州市，是一家以从事软 件和信息技术服务业为主的企业。企业注册资本154912.4692万人民币，实缴资本154912.4692万人民 币。公司法定代表人为张吕峥。 金融界消息 截至2025年8月15日收盘，创业慧康（300451）报收于5.39元，上涨1.89%，换手率3.61%， 成交量55.06万手，成交金额2.95亿元。 资金流向方面，今日主力资金净流出1576.15万元，占比成交额5.34%。其中，超大单净流出2487.70万 元、占成交额8.42%，大单净流入911.5 ...

Group 1 - The stock price of Chuangye Huikang is reported at 5.44 yuan, down 1.09% from the previous trading day [1] - The trading volume on that day was 281 million yuan, with a turnover rate of 3.38% [1] - Chuangye Huikang operates in the software development industry, focusing on medical information technology and AI healthcare [1] Group 2 - The company aims to optimize medical processes and improve diagnostic efficiency through intelligent technology, covering areas such as medical data management and clinical decision support [1] - Reports indicate that the AI healthcare industry is expected to reach a scale of 115.7 billion yuan by 2025, with Chuangye Huikang actively positioning itself in AI digital products [1] - On August 12, the net outflow of main funds for Chuangye Huikang was 14.2281 million yuan, with a cumulative net outflow of 334 million yuan over the past five days [1]

Group 1 - The stock of Chuangye Huikang (300451) closed at 5.45 yuan on August 8, 2025, down 6.68% with a turnover rate of 8.87% and a trading volume of 1.3544 million hands, resulting in a transaction amount of 756 million yuan [1][2] - On August 8, the net outflow of main funds was 198 million yuan, accounting for 26.16% of the total transaction amount, while retail investors had a net inflow of 139 million yuan, accounting for 18.38% [1][2] - The financing data on August 8 showed a financing buy of 53.9063 million yuan and a financing repayment of 111 million yuan, resulting in a net financing repayment of 56.8857 million yuan [1][2] Group 2 - Chuangye Huikang's total market value is 8.443 billion yuan, with a net asset of 4.462 billion yuan and a net profit of -15.6474 million yuan, ranking 129th in the industry [4] - The company's main business revenue for Q1 2025 was 290 million yuan, a year-on-year decrease of 22.67%, with a net profit attributable to shareholders of -15.6474 million yuan, a year-on-year decrease of 226.6% [4] - The company has shifted its main business focus from product development and sales to system construction, services, and operations, including areas such as smart healthcare, internet medical services, and health big data [4] Group 3 - In the last 90 days, three institutions have given ratings for the stock, with two buy ratings and one hold rating, and the average target price set by institutions is 6.13 yuan [5] - The financing balance on August 8 was 4.47 billion yuan, with a net financing buy of -56.8857 million yuan and a securities lending balance of 1.0578 million yuan [2][4] - The company's gross profit margin is 55.12%, which is higher than the industry average of 44.48% [4]

Core Insights - As of the last trading day on August 8, the pledge ratio of shareholders in Chuangyue Huikang reached 10.25% of the total share capital, ranking 923rd in the market [1] - Shareholders have pledged a total of 159 million shares, divided into 13 transactions, with a total market value of 865 million yuan [1] - Chuangyue Huikang focuses on the construction, research, and innovative services of healthcare information technology, offering a wide range of products including hospital information application software and various cloud platforms [1] Company Overview - Chuangyue Huikang Technology Co., Ltd. specializes in healthcare information technology, providing services such as hospital information systems, public health information systems, and mixed cloud internet hospital solutions [1] - The company has received recognition from the China Software Association for its contributions to the industry [1] - The chairman of the company is Zhang Lvzhen, and the general manager is Chen Zhongyang [1] Stock Performance - Over the past year, Chuangyue Huikang's stock has increased by 61.24% [1]

Group 1 - The latest stock price of Chuangye Huikang is 5.84 yuan, an increase of 0.04 yuan from the previous trading day [1] - The opening price was 5.82 yuan, with a highest point of 6.02 yuan and a lowest point of 5.81 yuan, and the trading volume reached 1.0472 million hands, with a transaction amount of 618 million yuan [1] - Chuangye Huikang operates in the software development industry, focusing on medical information technology, with products widely used in hospitals and community health service institutions [1] Group 2 - The company has received ratings from more than five institutions, indicating a positive outlook [1] - In the AI medical field, the company's business involves medical information solutions and has business synergies with some AI pharmaceutical companies [1] - On August 7, the net inflow of main funds was 13.1553 million yuan, accounting for 0.15% of the circulating market value, while the cumulative net outflow over the past five trading days was 106.2926 million yuan, accounting for 1.19% of the circulating market value [1]

Core Viewpoint - The company, Chuangyue Huikang, is facing significant challenges, including a sharp decline in profits and cash flow issues, leading to concerns about its future development prospects [1][5][6]. Shareholder Actions - Philips (China) Investment Co., Ltd., the second-largest shareholder, announced plans to sell 3% of its shares, which amounts to approximately 46.33 million shares, potentially raising around 276 million yuan based on the closing price of 5.96 yuan per share [2][3]. - The company's first major shareholder, Ge Hang, has also been reducing his stake, citing debt repayment and risk reduction as reasons for his actions [3][4]. Financial Performance - In 2024, Chuangyue Huikang reported a revenue of approximately 1.423 billion yuan, a year-on-year decrease of 11.96%, and a net profit of -174 million yuan, marking a dramatic decline of 572.96% [5][6]. - The company experienced a significant loss in the fourth quarter of 2024, which dragged the annual performance into negative territory, despite a profit of 52.75 million yuan in the first three quarters [5][6]. Cash Flow and Receivables - The company has a high level of accounts receivable, totaling 1.55 billion yuan, which exceeds its revenue and accounts for 27.35% of total assets, indicating potential cash flow issues [6][7]. - Operating cash flow decreased by 27.31% to 115 million yuan in 2024, exacerbating the company's cash flow challenges [6][7]. Future Outlook - The company anticipates continued pressure on profits into 2025, with a projected revenue of 290 million yuan in the first quarter, a year-on-year decrease of 22.67%, and a net profit of -15.64 million yuan, reflecting a decline of 226.6% [7]. - Management believes that the current difficulties are part of a phase of adjustment, with expectations for future growth driven by the integration of artificial intelligence and medical information technology [7].

Core Insights - The DRG/DIP concept increased by 1.00%, ranking 10th among concept sectors, with 11 stocks rising, including Jiarun Technology which hit a 20% limit up [1] - Major gainers in the sector included Jiahe Meikang, Wanda Information, and Taiji Co., with respective increases of 3.68%, 3.08%, and 2.98% [1] - The sector experienced a net outflow of 229 million yuan, with 10 stocks seeing net inflows, and Wanda Information leading with a net inflow of 65.92 million yuan [2][3] Sector Performance - The top-performing concept sectors included Rare Earth Permanent Magnet (+3.24%), Brain-Computer Interface (+2.69%), and Hyperbaric Oxygen Chamber (+2.56%), while the weight-loss drug sector saw a decline of -1.70% [2] - The DRG/DIP concept had a net inflow ratio led by Wanda Information at 10.09%, followed by ST Yilianzhong at 5.78% and Taiji Co. at 4.82% [3][4] Stock Specifics - Key stocks in the DRG/DIP concept included: - Wanda Information: +3.08%, net inflow of 65.92 million yuan, turnover rate of 5.34% [3] - Weining Health: +1.72%, net inflow of 62.81 million yuan, turnover rate of 6.37% [3] - Taiji Co.: +2.98%, net inflow of 42.14 million yuan, turnover rate of 5.36% [3] - Notable declines were seen in stocks like Maidi Technology (-2.61%) and Seli Medical (-2.32%), with significant net outflows [4]

Group 1: Agricultural Products - Company received approval from the China Securities Regulatory Commission for a stock issuance to specific targets, valid for 12 months from the date of approval [1] Group 2: Shareholder Reductions - Guangdong Science and Technology Venture Investment Co., Ltd. plans to reduce its stake in Hongqiang Co. by up to 211.6 million shares, representing 1% of total shares [1] - Huizhou Junqiang Equity Investment Partnership plans to reduce its stake in Green Precision by up to 123.8 million shares, representing 0.2995% of total shares [2] - Philips (China) Investment Co., Ltd. plans to reduce its stake in Chuangye Huikang by up to 46.33 million shares, representing 3% of total shares [2] - Chengdu Dijing Financial Consulting Center and Zhuo Yuqing plan to reduce their stake in Ruidi Zhichu by up to 194.65 million shares, representing 2.52% of total shares [4] - Ruizhong Life Insurance Co. plans to reduce its stake in Tongzhou Electronics by up to 752.44 million shares, representing 1% of total shares [5] - Zhejiang Taian Tai Investment Consulting Partnership plans to reduce its stake in Zhejiang Agricultural Shares by up to 15.2853 million shares, representing 3% of total shares [13] - Company executives plan to reduce their stake in Zhimi Intelligent by up to 47,000 shares, representing 0.0187% of total shares [18] Group 3: Financial Transactions - Shenzhen Metro Group will provide Vanke A with a loan of up to 1.681 billion yuan for debt repayment, with a term of no more than 3 years and an interest rate of 2.34% [6] - Sichuan Road and Bridge received a commitment letter for a stock repurchase loan of up to 180 million yuan from China Minsheng Bank, with a term of no more than 3 years [8] Group 4: Company Developments - Xiangyuan Cultural Tourism plans to upgrade the Danxia Mountain scenic area with a budget of approximately 26.8511 million yuan [7] - ST Kelly plans to sell a 36.9% stake in Jieno Medical and exit its investment in Jingzheng Medical [10] - Yifan Pharmaceutical's subsidiary's application for the registration of melatonin granules has been accepted by the National Medical Products Administration [12] - Aishide plans to acquire a 13.6365% stake in Gongqingcheng Aishide Innovation for approximately 1.0157 billion yuan [20] - Roman Co. intends to acquire a 39.23% stake in Wutong High-Tech, becoming its largest shareholder [22]

Shareholder Reduction - Chengdu Dijing and Zhuo Yuqing, shareholders of Ruidi Zhichu, plan to reduce their holdings by a total of no more than 2.52% [1] - Tongde Industrial, a shareholder of Foster, intends to reduce its holdings by no more than 32.5236 million shares [1] - Huizhou Junqiang, a shareholder of Green Precision, plans to reduce its holdings by no more than 1.238 million shares [1] - The National Integrated Circuit Fund, a shareholder of Debang Technology, plans to reduce its holdings by no more than 3% [1] - Zhang Lixin, chairman and core technical personnel of Chipeng Micro, intends to reduce his holdings by no more than 2.6262 million shares [1] - Qian Chunbo, director and deputy general manager of Chuhai Technology, plans to reduce his holdings by no more than 548,300 shares [1] - Tai'an Tai, a shareholder of Zhejiang Agricultural Shares, intends to reduce its holdings by no more than 3% [1] - UCM, a shareholder of Youde Precision, plans to reduce its holdings by no more than 1% [1] - Ruizhong Life Insurance, a shareholder of Tongzhou Electronics, intends to reduce its holdings by no more than 1% [1] - Guangdong Kechuang, a shareholder of Hongqiang Shares, plans to reduce its holdings by no more than 1% [1] Other Company News - Yibai Pharmaceutical received a "suspension of production and sales notice" from the Guizhou Provincial Drug Supervision Administration [1] - Zhongma Transmission is not involved in the robotics business [1]

Group 1 - The stock price of Chuangyue Huikang closed at 5.96 yuan on August 5, 2025, with an increase of 0.34% compared to the previous trading day [1] - The company reported a trading volume of 60.64 million shares and a transaction amount of 361 million yuan, with a turnover rate of 3.97% [1] - Chuangyue Huikang, established in 1997 and listed in 2015, operates in the software development industry, focusing on smart healthcare, smart sanitation, medical insurance, health, and elderly care information solutions [1] Group 2 - In 2024, the company's revenue composition indicated that the medical sector accounted for 93.25%, while the non-medical sector made up 6.75% [1] - On the evening of August 5, the company announced that its second-largest shareholder, Philips, plans to reduce its holdings by up to 46.33 million shares, representing 3% of the total share capital, with a proposed reduction amounting to approximately 276 million yuan based on the closing price [1] - For the first quarter of 2025, the company reported a revenue of 290 million yuan, a year-on-year decrease of 22.67%, and a net loss of 15.64 million yuan [1] Group 3 - On August 5, the net inflow of main funds was 8.47 million yuan, with a cumulative net inflow of 22.62 million yuan over the past five days [2]